A combination approach, which included metabolic reprogramming and immunotherapy, led to complete tumor regression in 60% of study mice.
Researchers have demonstrated that a new liquid biopsy approach overcomes traditional barriers to quickly and efficiently diagnose and monitor high-grade gliomas.
In mouse models of DIPG, simultaneously attacking two metabolic pathways led to significant improvements in survival.
Anti-androgen therapy showed positive results in cell lines and animal models.
Laboratory research paves the way for a clinical trial to see if an FDA-approved drug used to prevent organ transplant rejection can work against these aggressive brain tumors.